Intercept Pharma provides update on Phase III REVERSE trial of OCA for compensated cirrhosis due to NASH.
“Our teams continue to receive data and are working toward locking the database for our REVERSE study,” said Dr. M. Michelle Berrey, President of R&D and Chief Medical Officer. “As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022. There are no approved therapies for treatment of compensated cirrhosis due to NASH and we are focused on compiling this important data as soon as possible.”
REVERSE is the only active late-stage Phase III study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from REVERSE are being evaluated utilizing a new consensus methodology.
Intercept is also using this new methodology to compile a new data package from the Phase III REGENERATE study in liver fibrosis due to NASH for a potential resubmission meeting with FDA in the first half of 2022, if the data supports it.
Related news and insights
Innovent Biologics, Inc. and Eli Lilly and Company announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for Tyvyt (sintilimab injection) in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
Seagen Inc. announced full results from the pivotal phase II MOUNTAINEER trial , which showed Tukysa (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC).
Basilea Pharmaceutica Ltd., announced that its license partner, Pfizer Inc., has received a Drug Approval License from the National Medical Products Administration (NMPA) in China, for the intravenous formulation of Cresemba (isavuconazole) for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. This is the second approved formulation for Cresemba in China, in addition to the oral formulation for invasive aspergillosis and invasive mucormycosis.